ST316 + FOLFIRI + bevacizumab

ST316 + FOLFIRI + bevacizumab is a combination regimen consisting of **ST316** (an investigational agent; mechanism, class, and developer not defined in current public literature), plus the established chemotherapy regimen **FOLFIRI** (folinic acid [leucovorin], fluorouracil [5-FU], and irinotecan), and **bevacizumab** (a monoclonal antibody targeting vascular endothelial growth factor A). - FOLFIRI is a standard chemotherapy protocol primarily used for metastatic colorectal cancer, combining three drugs to inhibit DNA synthesis and promote cancer cell death. Fluorouracil disrupts DNA and RNA function, irinotecan inhibits topoisomerase I causing DNA damage, and folinic acid enhances 5-FU's action[1][2][3]. - Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding VEGF-A, starving tumors of their blood supply, and is commonly used in combination regimens for metastatic colorectal cancer. - ST316's mechanism is not defined in the current data, but as it is being tested in combination with FOLFIRI/bevacizumab, it is likely an investigational anticancer agent. No further mechanism, developer, or phase specifics for ST316 could be identified in available literature as of September 2025.